GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nurix Therapeutics Inc (NAS:NRIX) » Definitions » Total Current Liabilities

Nurix Therapeutics (Nurix Therapeutics) Total Current Liabilities : $87.62 Mil (As of Feb. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Nurix Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Nurix Therapeutics's total current liabilities for the quarter that ended in Feb. 2024 was $87.62

Nurix Therapeutics Total Current Liabilities Historical Data

The historical data trend for Nurix Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nurix Therapeutics Total Current Liabilities Chart

Nurix Therapeutics Annual Data
Trend Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Total Current Liabilities
Get a 7-Day Free Trial 16.14 44.54 66.26 70.66 86.96

Nurix Therapeutics Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.88 72.26 61.49 86.96 87.62

Nurix Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Nurix Therapeutics's Total Current Liabilities for the fiscal year that ended in Nov. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=15.317+7.489
+Other Current Liabilities+Current Deferred Liabilities
=16.054+48.098
=86.96

Nurix Therapeutics's Total Current Liabilities for the quarter that ended in Feb. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=16.737+7.31
+Other Current Liabilities+Current Deferred Liabilities
=17.499+46.077
=87.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Nurix Therapeutics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Nurix Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Nurix Therapeutics (Nurix Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nurix Therapeutics Inc (NAS:NRIX) » Definitions » Total Current Liabilities
Comparable Companies
AVIR VNDA OVID MGTX IGMS RPHM QURE PGEN FUSN KALV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
1700 Owens Street, Suite 205, San Francisco, CA, USA, 94158
Website
http://www.nurixtx.com
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Executives
Houte Hans Van officer: Chief Financial Officer C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Christine Ring officer: General Counsel C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Gwenn Hansen officer: Chief Scientific Officer C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Stefani Wolff officer: EVP and COO C/O PRINCIPIA BIOPHARMA INC., 400 EAST JAMIE COURT, SUITE 302, SOUTH SAN FRANCISCO CA 94080
Edward C Saltzman director C/O NURIX THERAPEUTICS, 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Paul M Silva director C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST, CAMBRIDGE MA 02139
Judith A Reinsdorf director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Pierre Beaurang officer: Chief Business Officer C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Clay B Siegall director 21823 30TH DR SE, BOTHELL WA 98021
Ponoi Capital, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Ii Management, Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Ponoi Capital Ii, Lp 10 percent owner 1700 OWENS STREET, STE 500, SAN FRANCISCO CA 94158
Column Group Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group L P 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Management, Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129

Nurix Therapeutics (Nurix Therapeutics) Headlines

From GuruFocus

Nurix Therapeutics to Participate in Upcoming Investor Conferences

By sperokesalga sperokesalga • 02-08-2023

Nurix Therapeutics Announces Clearance of Investigational New Drug Application for NX-5948 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

By Value_Insider Value_Insider • 12-15-2022

CFO Houte Van Sells 10,906 Shares of Nurix Therapeutics Inc

By GuruFocus Research • 12-21-2023

Nurix Therapeutics Announces Presentations at the 5th Annual Targeted Protein Degradation (TPD) Summit

By Value_Insider Value_Insider • 10-19-2022

Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

By Marketwired • 10-12-2023

Nurix Therapeutics to Participate in Upcoming Investor Conferences

By Ds*** Ds*** • 08-31-2022

Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting

By Value_Insider Value_Insider • 11-03-2022

Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin's Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit

By Value_Insider Value_Insider • 10-26-2022

Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

By Marketwired • 07-13-2023

Nurix Therapeutics Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer

By PurpleRose PurpleRose • 08-03-2022